Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation.

Authors:
Viergever BJ; Raats DAE; Geurts V; Mullenders J; Jonges TN and 4 more

Journal:
Br J Cancer

Publication Year: 2023

DOI:
10.1038/s41416-023-02494-6

PMCID:
PMC10844626

PMID:
38102228

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Br J Cancer

Abbreviation: Br J Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of…
Young Han C; Bedia JS; Yang WL and 19 more (2024) - Transparency Score: 3/6
Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and…
Su X; Jin K; Guo Q and 9 more (2024) - Transparency Score: 3/6
Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance…
Mah CY; Nguyen ADT; Niijima T and 12 more (2024) - Transparency Score: 4/6
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relaps…
Hogarty MD; Ziegler DS; Franson A and 15 more (2024) - Transparency Score: 3/6
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling i…
Mezquita L; Oulhen M; Aberlenc A and 9 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests BV: Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals. DR: Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals. VG, JE, TJ and JM declare no competing interests. MH: Research support from Bristol-Myers Squibb, AstraZeneca, Roche and 4SC; consultancy fees from Bristol-Myers Squibb, Merck, Roche, AstraZeneca, Seagen, Pfizer and Janssen (all paid to the Netherlands Cancer Institute). OK: Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals. RM: Advisory role (institutional): Merck, MSD, Janssen, Bristol-Myers Squibb. Research support (institutional): Janssen Pharmaceuticals, Astellas Pharmaceuticals."

Evidence found in paper:

"Funding This study was financially supported by Astellas Pharmaceuticals."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025